Immune Complexes and the Risk of CVD in Type 1 Diabetes
Authors:
- Maria F. Lopes-VirellaMLMaria F. Lopes-Virella
- Ionut BebuIBIonut Bebu
- Kelly J. HuntKHKelly J. Hunt
- Nathaniel L. BakerNBNathaniel L. Baker
- Barbara BraffettBBBarbara Braffett
- John M. LachinJLJohn M. Lachin
- the DCCT/EDIC Research GroupTGthe DCCT/EDIC Research Group
Open Access
- 19 June 2019
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 68 (9) , 1853-1860
Abstract
We investigated whether the composition of modified forms of LDL in circulating immune complexes (LDL-ICs) was associated with cardiovascular disease (CVD) outcomes, including any CVD, major adverse cardiac and cerebrovascular events (MACCE), myocardial infarction (MI), and coronary artery disease, in type 1 diabetes (T1D). Our results demonstrate that the baseline levels of oxidized LDL (oxLDL), MDA-modified LDL (MDA-LDL), and advanced glycosylation–modified LDL (AGE-LDL) in circulating ICs were associated with the four CVD outcomes in unadjusted models, and adjustment by age and mean HbA1c only resulted in minimal reduction of these associations. After adjustments were made for other cardiovascular risk factors, particularly LDL cholesterol, oxLDL-IC and MDA-LDL-IC remained independently associated with the risk of CVD, and oxLDL-IC was independently associated with the risk of MACCE and MI. In the majority of cases, the baseline levels of modified LDL-IC (measured many years before the occurrence of any CVD event) were associated with the risk of CVD over a 25-year period even after adjustment for other risk factors (including LDL cholesterol). Therefore, modified LDL biomarkers may help identify patients with T1D at high risk for MACCE and CVD events very early in the evolution of the disease, before other signals of disease are apparent.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-094176, U01-DK-094157)
This publication has 36 references indexed in Scilit:
- Levels of Oxidized LDL and Advanced Glycation End Products–Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 DiabetesDiabetes, 2011
- Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetesAtherosclerosis, 2010
- Development of Capture Assays for Different Modifications of Human Low-Density LipoproteinClinical and Vaccine Immunology, 2005
- Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodiesJournal of Lipid Research, 2004
- C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-α in the prognostic classification of unstable angina pectorisAnnals of Medicine, 2001
- Antibodies to Oxidized LDL and LDL-Containing Immune Complexes as Risk Factors for Coronary Artery Disease in Diabetes MellitusClinical Immunology, 1999
- Diagnostic Value of Immune Cholesterol as a Marker for AtherosclerosisEuropean Journal of Preventive Cardiology, 1995
- Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.Journal of Clinical Investigation, 1995
- Lipid and Lipoprotein Levels in Patients With IDDM: Diabetes Control and Complication Trial ExperienceDiabetes Care, 1992
- Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.Journal of Clinical Investigation, 1989